Brokerages expect Antares Pharma, Inc. (NASDAQ:ATRS) to announce sales of $12.99 million for the current quarter, Zacks Investment Research reports. Five analysts have provided estimates for Antares Pharma’s earnings. The highest sales estimate is $14.09 million and the lowest is $11.64 million. Antares Pharma reported sales of $12.23 million in the same quarter last year, which indicates a positive year over year growth rate of 6.2%. The firm is expected to issue its next earnings report on Tuesday, August 8th.
On average, analysts expect that Antares Pharma will report full-year sales of $12.99 million for the current financial year, with estimates ranging from $49.19 million to $58.90 million. For the next year, analysts forecast that the company will report sales of $98.18 million per share, with estimates ranging from $80.50 million to $135.64 million. Zacks Investment Research’s sales calculations are an average based on a survey of research firms that follow Antares Pharma.
Antares Pharma (NASDAQ:ATRS) last released its quarterly earnings data on Tuesday, May 9th. The specialty pharmaceutical company reported ($0.03) EPS for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.01. Antares Pharma had a negative return on equity of 45.05% and a negative net margin of 41.26%. The business had revenue of $12.01 million for the quarter, compared to the consensus estimate of $12.10 million.
Several equities analysts have recently issued reports on the company. Vetr upgraded Antares Pharma from a “buy” rating to a “strong-buy” rating and set a $3.42 price objective for the company in a research report on Monday, July 24th. HC Wainwright reiterated a “buy” rating and set a $5.00 price objective on shares of Antares Pharma in a research report on Friday, June 23rd. Chardan Capital assumed coverage on Antares Pharma in a research report on Friday, June 23rd. They set a “buy” rating and a $5.00 price objective for the company. Piper Jaffray Companies set a $4.00 price objective on Antares Pharma and gave the stock a “buy” rating in a research report on Wednesday, July 26th. Finally, Raymond James Financial, Inc. assumed coverage on Antares Pharma in a research report on Thursday, April 20th. They set a “strong-buy” rating and a $4.30 price objective for the company. One investment analyst has rated the stock with a hold rating, three have issued a buy rating and two have assigned a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $3.83.
In other news, insider Fred M. Powell bought 130,000 shares of the business’s stock in a transaction on Friday, June 9th. The stock was purchased at an average cost of $2.79 per share, for a total transaction of $362,700.00. Following the completion of the transaction, the insider now directly owns 331,434 shares of the company’s stock, valued at approximately $924,700.86. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 11.60% of the company’s stock.
A number of large investors have recently added to or reduced their stakes in the company. Legal & General Group Plc purchased a new stake in Antares Pharma during the second quarter worth $120,000. Credit Suisse AG purchased a new stake in Antares Pharma during the first quarter worth $146,000. National Planning Corp increased its stake in Antares Pharma by 11.5% in the second quarter. National Planning Corp now owns 58,233 shares of the specialty pharmaceutical company’s stock worth $186,000 after buying an additional 6,000 shares during the period. KCG Holdings Inc. increased its stake in Antares Pharma by 48.8% in the first quarter. KCG Holdings Inc. now owns 66,717 shares of the specialty pharmaceutical company’s stock worth $189,000 after buying an additional 21,881 shares during the period. Finally, Thompson Davis & CO. Inc. increased its stake in Antares Pharma by 80.8% in the first quarter. Thompson Davis & CO. Inc. now owns 68,386 shares of the specialty pharmaceutical company’s stock worth $194,000 after buying an additional 30,560 shares during the period. Hedge funds and other institutional investors own 31.70% of the company’s stock.
Antares Pharma (NASDAQ ATRS) opened at 3.14 on Wednesday. The stock’s market cap is $489.61 million. The stock has a 50 day moving average price of $3.14 and a 200-day moving average price of $2.74. Antares Pharma has a 12-month low of $1.01 and a 12-month high of $3.37.
Antares Pharma Company Profile
Antares Pharma, Inc (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops, manufactures and commercializes therapeutic products using its drug delivery systems. Its subcutaneous injection technology platforms include VIBEX disposable pressure-assisted auto injector system suitable for branded and generic injectable drugs in unit dose containers, reusable needle-free spring-action injector devices, and disposable multi-use pen injectors for use with cartridges.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
What are top analysts saying about Antares Pharma Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Antares Pharma Inc. and related companies.